Three rapid clinical updates — tenecteplase for stroke, the danger of overshooting blood pressure after ICH, and the new Surviving Sepsis guidelines ACEP won’t endorse — then The Pitt S1E03 on death, grief, hot debriefs and caring for culturally diverse patients in the ED. Hosts: Dr Shreyas Iyer, Dr Caroline Wilson, Dr Pramod Chandru, Dr Mariez Gorgi 🎞️ Episode Synopsis (AI) The team opens with three rapid clinical updates. Caroline covers the shift in acute ischaemic stroke care towards tenecteplase as the preferred thrombolytic in place of alteplase, prompted by the NSW ACI clinical practice guide, and discusses the extended 4.5–9 hour and wake-up stroke windows, the role of perfusion imaging, and the value of the Telestroke service in regional NSW. Pramod presents a recent paper showing that overshooting blood pressure targets after intracerebral haemorrhage is associated with worse outcomes, using it as a springboard into a broader, sceptical discussion of evidence standards, trial design, and the harms of overzealous blood pressure lowering. Pramod closes the updates with breaking news: the release of the 2026 Surviving Sepsis Campaign guidelines and ACEP’s decision not to endorse them, unpacking the three stated concerns. The conversation then turns to The Pitt’s third episode, which the team uses to explore death and grief in emergency practice — first deaths, the weight of decision-making as a junior, and the experiences that stay with clinicians for years. They examine the role and limits of the hot debrief, how senior and junior staff draw different value from it, and practical ways to look after a team after a difficult case. The episode finishes on the show’s portrayal of an interpreter transforming care for a culturally and linguistically diverse patient, and the team’s reflections on advocating for diverse communities in a time-pressured ED. ⏱️ Episode Timestamps00:00 — Disclaimer & intro00:28 — Welcome & introductions (first-time guest Mariez Gorgi)01:06 — Update 1: Stroke thrombolysis — Tenecteplase replacing alteplase (Caroline)11:43 — Update 2: Blood pressure control after ICH — overshooting and harm (Pramod)21:30 — Update 3: 2026 Surviving Sepsis guidelines & ACEP non-endorsement (Pramod)25:48 — The Pitt S1E03 — episode recap (Mariez)27:51 — Death & grief in emergency medicine42:31 — Hot debriefs: value, pitfalls, and looking after staff57:12 — Interpreters & culturally and linguistically diverse patients62:20 — Wrap-up & what’s coming 📚 References & Resources (in order of discussion) NSW Agency for Clinical Innovation (February 2026) — Intravenous thrombolysis for adult patients with acute ischaemic stroke: clinical practice guide.🔗 ACI clinical practice guide (PDF)⏱️ ~01:06Names tenecteplase as the preferred first-line IV thrombolytic; alteplase remains an effective TGA-approved alternative. Also addresses the extended 4.5–9 hour / wake-up window (beyond 4.5 h is outside TGA approval and reserved for specialist-led decisions). Primary source for Caroline’s update, including the small functional-outcome benefit cited from its underpinning evidence base. Shi AC, Taylor T, Huang C-C, Singhal AB, Goldstein JN, Bevers MB, Hou PC (2025) — Early Intensive Blood Pressure Reduction After Intracerebral Hemorrhage Is Associated With Worse Functional Outcome: The Risk of Overshooting Blood Pressure Goals. Annals of Emergency Medicine.🔗 Annals of Emergency Medicine⏱️ ~11:43Retrospective cohort (two academic centres, 2017–2023). Overshooting to 120 mmHg systolic associated with worse functional outcome — the paper Pramod presents. Anderson CS, et al. (2013) — Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral Hemorrhage (INTERACT2). New England Journal of Medicine.🔗 NEJM⏱️ ~15:24Foundational RCT on early intensive BP lowering in ICH. INTERACT3 (Lancet 2023) and the Moullaali et al. preplanned pooled individual-patient-data analysis (referenced as “a pooled analysis”) extend this evidence base. Préterre C, Gaultier A, Obadia M, et al. (2025) — Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4·5 h of severe vision loss (THEIA): a multicentre, double-dummy, patient-blinded and assessor-blinded, randomised, controlled, phase 3 trial. The Lancet Neurology.🔗 The Lancet Neurology⏱️ ~16:40The trial Pramod uses to illustrate trial-design and power pitfalls. Visual-acuity improvement was 66% with alteplase vs 48% with oral aspirin — an ~18-point difference that did not reach significance, in a trial the authors judged underpowered (improvement in both arms ran well above the ~40% vs ~10% the study was designed to expect). Surviving Sepsis Campaign (2026) — Prescott H, Antonelli M, Alhazzani W, et al. International Guidelines for Management of Sepsis and Septic Shock 2026. Critical Care Medicine / Intensive Care Medicine.🔗 Surviving Sepsis Campaign 2026 (SCCM)⏱️ ~21:30The new SSC guidelines; for the first time, separate adult and paediatric documents — central to the discussion. American College of Emergency Physicians (2 February 2026) — ACEP Will Not Endorse New Sepsis Guidelines from the Surviving Sepsis Campaign.🔗 ACEP statement⏱️ ~21:48ACEP’s formal statement citing three concerns: conflicting adult vs paediatric guidance, guidelines not reflecting the reality of emergency care, and the absence of emergency-physician governance in the SSC. The Pitt — Season 1, Episode 3 (Max, 2025).⏱️ ~25:48The episode under discussion; basis for the death/grief, hot-debrief and interpreter themes. 📬 Contact the TeamWe value your feedback and would love to hear from you! Email us at hello@n5em.com
